OTCMKTS:RNUGF ReNeuron Group (RNUGF) Stock Price, News & Analysis → Elon’s New A.I. Device is About to Shock the World (From InvestorPlace) (Ad) Free RNUGF Stock Alerts $0.05 +0.05 (+4,500.00%) (As of 04/26/2024 08:54 PM ET) Add Compare Share Share Today's Range$0.05▼$0.0550-Day Range$0.00▼$0.0552-Week Range$0.00▼$0.05Volume200 shsAverage Volume1,567 shsMarket Capitalization$2.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartShort InterestStock AnalysisChartShort Interest Get ReNeuron Group alerts: Email Address Ad InvestorPlaceElon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About ReNeuron Group Stock (OTCMKTS:RNUGF)ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.Read More RNUGF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNUGF Stock News HeadlinesOctober 18, 2023 | investing.comRugvista Group AB (RUG)April 3, 2023 | proactiveinvestors.comReNeuron appoints new scientific advisory boardApril 29, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” February 17, 2023 | proactiveinvestors.comReNeuron has extended cash runway as it focuses on validating its exosome platformDecember 8, 2022 | proactiveinvestors.comReNeuron says positive iPSC data presented at conferenceDecember 8, 2022 | proactiveinvestors.comReNeuron Group says positive iPSC data presented at conferenceDecember 2, 2022 | proactiveinvestors.comReNeuron unveils jump in revenue for first-half of 2022; issues a funding updateNovember 3, 2022 | finance.yahoo.comReNeuron Group (RENE): Re-initiation - Rebranding in Exosome Targeted Drug DeliveryApril 29, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” September 14, 2022 | markets.businessinsider.comReNeuron Group Names John Hawkins CFO - Quick FactsSee More Headlines Receive RNUGF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/29/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:RNUGF Previous SymbolNASDAQ:RNUGF CUSIPN/A CIKN/A Webwww.reneuron.com Phone44-20-3819-8400FaxN/AEmployees26Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.08 Current Ratio1.51 Quick RatioN/A Sales & Book Value Annual Sales$640,000.00 Price / Sales4.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book0.46Miscellaneous Outstanding Shares57,170,000Free FloatN/AMarket Cap$2.89 million OptionableNot Optionable Beta0.52 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Iain Gladstone Ross B.Sc. (Age 70)BSc (Hons), C.DIR, CH.D, Executive Chairman Comp: $535.43kMr. John Michael Hawkins A.C.A. (Age 58)Company Secretary, CFO & Director Comp: $240.21kDr. John David Sinden B.A. (Age 73)BA, M.A., MA, Ph.D., Co-Founder Comp: $128.25kMs. Suzanne HancockChief Operations OfficerDr. Randolph Corteling Ph.D.Chief Scientific OfficerMr. Simon DewChief Business OfficerMore ExecutivesKey CompetitorsAmarantus BioScienceOTCMKTS:AMBSPropanc BiopharmaOTCMKTS:PPCBBoomerOTCMKTS:BOMHSunwin Stevia InternationalOTCMKTS:SUWNU.S. Stem CellOTCMKTS:USRMView All Competitors RNUGF Stock Analysis - Frequently Asked Questions How have RNUGF shares performed in 2024? ReNeuron Group's stock was trading at $0.0515 at the start of the year. Since then, RNUGF shares have decreased by 1.7% and is now trading at $0.0506. View the best growth stocks for 2024 here. How do I buy shares of ReNeuron Group? Shares of RNUGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:RNUGF) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReNeuron Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
